Bioengineer Gang Bao uses gene editing to repair up to 40 percent of bone marrow cells from patients
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.
Bao, in collaboration with Baylor College of Medicine, Texas Children’s Hospital and Stanford University, is working to find a cure for the hereditary disease. A single DNA mutation causes the body to make sticky, crescent-shaped red blood cells that contain abnormal hemoglobin and can block blood flow in limbs and organs.
In his talk at the annual American Association for the Advancement of Science meeting in Austin Feb. 16, Bao revealed results from a series of tests to see whether CRISPR/Cas9-based editing can fix the mutation. His presentation was part of a scientific session titled “Gene Editing and Human Identity: Promising Advances and Ethical Challenges.”
“Sickle cell disease is caused by a single mutation in the beta-globin gene (in the stem cell’s DNA),” he said. “The idea is to correct that particular mutation, and then stem cells that have the correction would differentiate into normal blood cells, including red blood cells. Those will then be healthy blood cells.”
Bao’s lab collaborated with Vivien Sheehan, an assistant professor of pediatrics and hematology at Baylor and a member of the sickle cell program at Texas Children’s, to collect stem and progenitor cells (CD34-positive cells) from patients with the disease. These were then edited in the Bao lab with CRISPR/Cas9 together with a custom template, a piece of DNA designed to correct the mutation.
The gene-edited cells were injected into the bone marrow of immunodeficient mice and tested after 19 weeks to see how many retained the edit. “The rate of repair remained stable, which is great,” Bao said. This engraftment study was carried out in the lab of Matt Porteus, an associate professor of pediatrics at Stanford.
Another major finding of the study is that the CRISPR/Cas9 system could introduce large alterations to the genes in patients’ cells, in addition to small mutations or deletions. These off-target effects could cause a disease.
The findings, part of an upcoming paper, are a step toward treating sickle cell disease. Obstacles in the way of a cure include optimizing the CRISPR/Cas9 system to eliminate off-target effects, as well as finding a way to further increase the amount of gene-corrected stem cells.
Bao pointed out that researchers still don’t know whether repairing as much as 40 percent of the cells is enough to cure a patient. “We’d like to say, ‘Yes,’” he said, “but we don’t really know yet. That’s something we hope to learn from an eventual clinical trial.”
Learn more: Rice U. reports progress in pursuit of sickle cell cure
The Latest on: Sickle cell disease
[google_news title=”” keyword=”Sickle cell disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Sickle cell disease
- 'Life-changing' sickle cell disease treatment made available on NHSon May 3, 2024 at 1:17 pm
A "life-changing" new treatment for people living with sickle cell disease is to be made available on the NHS. Around 4,000 people living with the potentially fatal blood disorder could see their ...
- NHS approves 'transformative' sickle cell treatment in Englandon May 3, 2024 at 10:38 am
Four thousand people diagnosed with sickle cell disease in England may now access "life-changing" treatment following its approval for NHS use. This treatment, known as voxelotor or oxbryta, and ...
- NHS approves 'life-changing' new sickle cell treatment for thousands of Britson May 3, 2024 at 4:30 am
The drug, known as voxelotor, will be available immediately and could benefit around 4,000 people with sickle cell disease in England. It will significantly improve the quality of life for patients ...
- NHS to provide Pfizer’s Voxelotor to treat sickle cell diseaseon May 2, 2024 at 11:22 pm
The UK's National Health Service (NHS) has announced plans to offer Pfizer's Voxelotor (Oxbryta), a new treatment option for sickle cell disease patients. The latest development comes after the ...
- A call for state funding for promising sickle cell disease treatmenton May 2, 2024 at 5:00 pm
Sickle cell disease is an incredibly painful genetic blood disorder. Those familiar with this disease know that it makes a normal life extremely difficult to manage. Although the Black community is ...
- ‘Transformative’ sickle cell treatment approved for NHS useon May 2, 2024 at 4:17 pm
Around 4,000 people with sickle cell disease in England could benefit from a “life-changing” new treatment after it was given the green light for use in the NHS. Health leaders said that voxelotor, ...
- ‘Life-changing’ sickle cell drug approved for NHS roll-out after patient-led campaignon May 2, 2024 at 4:11 pm
Despite being the fastest-growing genetic condition in the UK, sickle cell disorder has historically been underserved by treatment options.
- NHS rolls out ‘life-changing’ treatment for thousands with sickle cell diseaseon May 2, 2024 at 4:06 pm
Voxelotor (Oxbryta®) will be administered in the form of a tablet taken once a day for eligible patients and could help reduce the need for blood transfusions and lead to fewer hospital appointments.
- ‘Life-changing’ drug for sickle cell disease to be offered by NHS in Englandon May 2, 2024 at 3:05 pm
Voxelotor, which can help reduce need for blood transfusions, is administered as a daily tablet ...
- CDSD student's death sparks questions, what is sickle cell disease?on April 30, 2024 at 1:51 pm
According to the Dauphin County Coroner's Office, 16-year-old Justin Johnson died of complications of sickle cell disease.
via Bing News